Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

S9908: Glutamine in Treating Mucositis Caused by Radiation Therapy in Patients With Newly Diagnosed Cancer of the Mouth or Throat
S9908, A Double-Blind, Placebo-Controlled Trial To Study The Efficacy And Safety Of L-Glutamine (In AES0014 Delivery Vehicle) Upon Radiation Therapy-Induced Oral Mucositis In Head and Neck Cancer Patients, Phase III
Status: Enrolling
Updated:  11/17/2015
Swedish Cancer Institute at Swedish Medical Center - First Hill Campus
mi
from
Seattle, WA
S9908: Glutamine in Treating Mucositis Caused by Radiation Therapy in Patients With Newly Diagnosed Cancer of the Mouth or Throat
S9908, A Double-Blind, Placebo-Controlled Trial To Study The Efficacy And Safety Of L-Glutamine (In AES0014 Delivery Vehicle) Upon Radiation Therapy-Induced Oral Mucositis In Head and Neck Cancer Patients, Phase III
Status: Enrolling
Updated: 11/17/2015
Swedish Cancer Institute at Swedish Medical Center - First Hill Campus
mi
from
Seattle, WA
Click here to add this to my saved trials
S9908: Glutamine in Treating Mucositis Caused by Radiation Therapy in Patients With Newly Diagnosed Cancer of the Mouth or Throat
S9908, A Double-Blind, Placebo-Controlled Trial To Study The Efficacy And Safety Of L-Glutamine (In AES0014 Delivery Vehicle) Upon Radiation Therapy-Induced Oral Mucositis In Head and Neck Cancer Patients, Phase III
Status: Enrolling
Updated:  11/17/2015
Veterans Affairs Medical Center - Seattle
mi
from
Seattle, WA
S9908: Glutamine in Treating Mucositis Caused by Radiation Therapy in Patients With Newly Diagnosed Cancer of the Mouth or Throat
S9908, A Double-Blind, Placebo-Controlled Trial To Study The Efficacy And Safety Of L-Glutamine (In AES0014 Delivery Vehicle) Upon Radiation Therapy-Induced Oral Mucositis In Head and Neck Cancer Patients, Phase III
Status: Enrolling
Updated: 11/17/2015
Veterans Affairs Medical Center - Seattle
mi
from
Seattle, WA
Click here to add this to my saved trials
S9908: Glutamine in Treating Mucositis Caused by Radiation Therapy in Patients With Newly Diagnosed Cancer of the Mouth or Throat
S9908, A Double-Blind, Placebo-Controlled Trial To Study The Efficacy And Safety Of L-Glutamine (In AES0014 Delivery Vehicle) Upon Radiation Therapy-Induced Oral Mucositis In Head and Neck Cancer Patients, Phase III
Status: Enrolling
Updated:  11/17/2015
CCOP - Northwest
mi
from
Tacoma, WA
S9908: Glutamine in Treating Mucositis Caused by Radiation Therapy in Patients With Newly Diagnosed Cancer of the Mouth or Throat
S9908, A Double-Blind, Placebo-Controlled Trial To Study The Efficacy And Safety Of L-Glutamine (In AES0014 Delivery Vehicle) Upon Radiation Therapy-Induced Oral Mucositis In Head and Neck Cancer Patients, Phase III
Status: Enrolling
Updated: 11/17/2015
CCOP - Northwest
mi
from
Tacoma, WA
Click here to add this to my saved trials
S9908: Glutamine in Treating Mucositis Caused by Radiation Therapy in Patients With Newly Diagnosed Cancer of the Mouth or Throat
S9908, A Double-Blind, Placebo-Controlled Trial To Study The Efficacy And Safety Of L-Glutamine (In AES0014 Delivery Vehicle) Upon Radiation Therapy-Induced Oral Mucositis In Head and Neck Cancer Patients, Phase III
Status: Enrolling
Updated:  11/17/2015
Madigan Army Medical Center
mi
from
Tacoma, WA
S9908: Glutamine in Treating Mucositis Caused by Radiation Therapy in Patients With Newly Diagnosed Cancer of the Mouth or Throat
S9908, A Double-Blind, Placebo-Controlled Trial To Study The Efficacy And Safety Of L-Glutamine (In AES0014 Delivery Vehicle) Upon Radiation Therapy-Induced Oral Mucositis In Head and Neck Cancer Patients, Phase III
Status: Enrolling
Updated: 11/17/2015
Madigan Army Medical Center
mi
from
Tacoma, WA
Click here to add this to my saved trials
S9908: Glutamine in Treating Mucositis Caused by Radiation Therapy in Patients With Newly Diagnosed Cancer of the Mouth or Throat
S9908, A Double-Blind, Placebo-Controlled Trial To Study The Efficacy And Safety Of L-Glutamine (In AES0014 Delivery Vehicle) Upon Radiation Therapy-Induced Oral Mucositis In Head and Neck Cancer Patients, Phase III
Status: Enrolling
Updated:  11/17/2015
Hospital for Sick Children
mi
from
Toronto,
S9908: Glutamine in Treating Mucositis Caused by Radiation Therapy in Patients With Newly Diagnosed Cancer of the Mouth or Throat
S9908, A Double-Blind, Placebo-Controlled Trial To Study The Efficacy And Safety Of L-Glutamine (In AES0014 Delivery Vehicle) Upon Radiation Therapy-Induced Oral Mucositis In Head and Neck Cancer Patients, Phase III
Status: Enrolling
Updated: 11/17/2015
Hospital for Sick Children
mi
from
Toronto,
Click here to add this to my saved trials
Post-Operative Chemoradiation for Extremity & Trunk Soft Tissue Sarcoma
A Phase I Study of Post-Operative Concurrent Chemoradiation for Extremity and Trunk Soft Tissue Sarcoma
Status: Enrolling
Updated:  11/17/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Post-Operative Chemoradiation for Extremity & Trunk Soft Tissue Sarcoma
A Phase I Study of Post-Operative Concurrent Chemoradiation for Extremity and Trunk Soft Tissue Sarcoma
Status: Enrolling
Updated: 11/17/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Multimodality Phase II Study in Prostate Cancer
Multimodality Therapy for Recurrent High Risk Prostate Cancer: A Phase II Study
Status: Enrolling
Updated:  11/18/2015
Johns Hopkins University
mi
from
Baltimore, MD
Multimodality Phase II Study in Prostate Cancer
Multimodality Therapy for Recurrent High Risk Prostate Cancer: A Phase II Study
Status: Enrolling
Updated: 11/18/2015
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Multimodality Phase II Study in Prostate Cancer
Multimodality Therapy for Recurrent High Risk Prostate Cancer: A Phase II Study
Status: Enrolling
Updated:  11/18/2015
The Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Multimodality Phase II Study in Prostate Cancer
Multimodality Therapy for Recurrent High Risk Prostate Cancer: A Phase II Study
Status: Enrolling
Updated: 11/18/2015
The Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Multimodality Phase II Study in Prostate Cancer
Multimodality Therapy for Recurrent High Risk Prostate Cancer: A Phase II Study
Status: Enrolling
Updated:  11/18/2015
Duke University
mi
from
Durham, NC
Multimodality Phase II Study in Prostate Cancer
Multimodality Therapy for Recurrent High Risk Prostate Cancer: A Phase II Study
Status: Enrolling
Updated: 11/18/2015
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer
A Multinational, Randomized, Double Blind, Controlled Phase II Trial of Ombrabulin With Taxane and Platinum Combination Administered Every Three Weeks, in First Line Treatment of Patients Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  11/18/2015
Clinical Research Facility
mi
from
Muscle Shoals, AL
Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer
A Multinational, Randomized, Double Blind, Controlled Phase II Trial of Ombrabulin With Taxane and Platinum Combination Administered Every Three Weeks, in First Line Treatment of Patients Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 11/18/2015
Clinical Research Facility
mi
from
Muscle Shoals, AL
Click here to add this to my saved trials
Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer
A Multinational, Randomized, Double Blind, Controlled Phase II Trial of Ombrabulin With Taxane and Platinum Combination Administered Every Three Weeks, in First Line Treatment of Patients Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  11/18/2015
Clinical Research Facility
mi
from
Hot Springs, AR
Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer
A Multinational, Randomized, Double Blind, Controlled Phase II Trial of Ombrabulin With Taxane and Platinum Combination Administered Every Three Weeks, in First Line Treatment of Patients Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 11/18/2015
Clinical Research Facility
mi
from
Hot Springs, AR
Click here to add this to my saved trials
Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer
A Multinational, Randomized, Double Blind, Controlled Phase II Trial of Ombrabulin With Taxane and Platinum Combination Administered Every Three Weeks, in First Line Treatment of Patients Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  11/18/2015
Clinical Research Facility
mi
from
Anaheim, CA
Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer
A Multinational, Randomized, Double Blind, Controlled Phase II Trial of Ombrabulin With Taxane and Platinum Combination Administered Every Three Weeks, in First Line Treatment of Patients Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 11/18/2015
Clinical Research Facility
mi
from
Anaheim, CA
Click here to add this to my saved trials
Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer
A Multinational, Randomized, Double Blind, Controlled Phase II Trial of Ombrabulin With Taxane and Platinum Combination Administered Every Three Weeks, in First Line Treatment of Patients Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  11/18/2015
Clinical Research Facility
mi
from
Modesto, CA
Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer
A Multinational, Randomized, Double Blind, Controlled Phase II Trial of Ombrabulin With Taxane and Platinum Combination Administered Every Three Weeks, in First Line Treatment of Patients Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 11/18/2015
Clinical Research Facility
mi
from
Modesto, CA
Click here to add this to my saved trials
Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer
A Multinational, Randomized, Double Blind, Controlled Phase II Trial of Ombrabulin With Taxane and Platinum Combination Administered Every Three Weeks, in First Line Treatment of Patients Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  11/18/2015
Clinical Research Facility
mi
from
Lansing, MI
Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer
A Multinational, Randomized, Double Blind, Controlled Phase II Trial of Ombrabulin With Taxane and Platinum Combination Administered Every Three Weeks, in First Line Treatment of Patients Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 11/18/2015
Clinical Research Facility
mi
from
Lansing, MI
Click here to add this to my saved trials
Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer
A Multinational, Randomized, Double Blind, Controlled Phase II Trial of Ombrabulin With Taxane and Platinum Combination Administered Every Three Weeks, in First Line Treatment of Patients Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated:  11/18/2015
Investigational Site Number 036002
mi
from
Bendigo,
Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer
A Multinational, Randomized, Double Blind, Controlled Phase II Trial of Ombrabulin With Taxane and Platinum Combination Administered Every Three Weeks, in First Line Treatment of Patients Metastatic Non-small Cell Lung Cancer
Status: Enrolling
Updated: 11/18/2015
Investigational Site Number 036002
mi
from
Bendigo,
Click here to add this to my saved trials
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rate Tumors of Neuroendocrine Origin
Status: Enrolling
Updated:  11/18/2015
Cedars Sinai Medical Center The Pituitary Center (3)
mi
from
Los Angeles, CA
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rate Tumors of Neuroendocrine Origin
Status: Enrolling
Updated: 11/18/2015
Cedars Sinai Medical Center The Pituitary Center (3)
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rate Tumors of Neuroendocrine Origin
Status: Enrolling
Updated:  11/18/2015
Cedars Sinai Medical Center Cedars Sinai 4
mi
from
Los Angeles, CA
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rate Tumors of Neuroendocrine Origin
Status: Enrolling
Updated: 11/18/2015
Cedars Sinai Medical Center Cedars Sinai 4
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rate Tumors of Neuroendocrine Origin
Status: Enrolling
Updated:  11/18/2015
Stanford University Medical Center SC
mi
from
Stanford, CA
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rate Tumors of Neuroendocrine Origin
Status: Enrolling
Updated: 11/18/2015
Stanford University Medical Center SC
mi
from
Stanford, CA
Click here to add this to my saved trials
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rate Tumors of Neuroendocrine Origin
Status: Enrolling
Updated:  11/18/2015
Dana Farber Cancer Institute Deptof DanaFarberCancerInst(5)
mi
from
Boston, MA
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rate Tumors of Neuroendocrine Origin
Status: Enrolling
Updated: 11/18/2015
Dana Farber Cancer Institute Deptof DanaFarberCancerInst(5)
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rate Tumors of Neuroendocrine Origin
Status: Enrolling
Updated:  11/18/2015
Mount Sinai School of Medicine Study Coordinator
mi
from
New York, NY
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rate Tumors of Neuroendocrine Origin
Status: Enrolling
Updated: 11/18/2015
Mount Sinai School of Medicine Study Coordinator
mi
from
New York, NY
Click here to add this to my saved trials
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rate Tumors of Neuroendocrine Origin
Status: Enrolling
Updated:  11/18/2015
Swedish Medical Center Dept.ofSwedishMedicalCtr.(2)
mi
from
Seattle, WA
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rate Tumors of Neuroendocrine Origin
Status: Enrolling
Updated: 11/18/2015
Swedish Medical Center Dept.ofSwedishMedicalCtr.(2)
mi
from
Seattle, WA
Click here to add this to my saved trials
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rate Tumors of Neuroendocrine Origin
Status: Enrolling
Updated:  11/18/2015
Novartis Investigative Site
mi
from
Buenos Aires,
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rate Tumors of Neuroendocrine Origin
Status: Enrolling
Updated: 11/18/2015
Novartis Investigative Site
mi
from
Buenos Aires,
Click here to add this to my saved trials
BKM120 in Metastatic Castration-resistant Prostate Cancer
Phase II Study of BKM120 in Men With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  11/18/2015
Duke Cancer Institute
mi
from
Durham, NC
BKM120 in Metastatic Castration-resistant Prostate Cancer
Phase II Study of BKM120 in Men With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 11/18/2015
Duke Cancer Institute
mi
from
Durham, NC
Click here to add this to my saved trials
BKM120 in Metastatic Castration-resistant Prostate Cancer
Phase II Study of BKM120 in Men With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  11/18/2015
OHSU Knight Cancer Institute
mi
from
Portland, OR
BKM120 in Metastatic Castration-resistant Prostate Cancer
Phase II Study of BKM120 in Men With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 11/18/2015
OHSU Knight Cancer Institute
mi
from
Portland, OR
Click here to add this to my saved trials
BKM120 in Metastatic Castration-resistant Prostate Cancer
Phase II Study of BKM120 in Men With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  11/18/2015
Univ of Washington
mi
from
Seattle, WA
BKM120 in Metastatic Castration-resistant Prostate Cancer
Phase II Study of BKM120 in Men With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 11/18/2015
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors
An Open-label, Multi-center Phase I Dose-finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  11/18/2015
Highlands Oncology Group Dept of Highlands Oncology Grp
mi
from
Fayetteville, AR
Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors
An Open-label, Multi-center Phase I Dose-finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 11/18/2015
Highlands Oncology Group Dept of Highlands Oncology Grp
mi
from
Fayetteville, AR
Click here to add this to my saved trials
Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors
An Open-label, Multi-center Phase I Dose-finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  11/18/2015
Medical University of South Carolina SC
mi
from
Charleston, SC
Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors
An Open-label, Multi-center Phase I Dose-finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 11/18/2015
Medical University of South Carolina SC
mi
from
Charleston, SC
Click here to add this to my saved trials
Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors
An Open-label, Multi-center Phase I Dose-finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  11/18/2015
Washington University School of Medicine Washington University (16)
mi
from
St. Louis, MO
Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors
An Open-label, Multi-center Phase I Dose-finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 11/18/2015
Washington University School of Medicine Washington University (16)
mi
from
St. Louis, MO
Click here to add this to my saved trials
Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors
An Open-label, Multi-center Phase I Dose-finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  11/18/2015
Novartis Investigative Site
mi
from
Wilrijk,
Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors
An Open-label, Multi-center Phase I Dose-finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 11/18/2015
Novartis Investigative Site
mi
from
Wilrijk,
Click here to add this to my saved trials
Patient Factors Impacting Adherence to Oral Chemotherapy
A Pilot Study to Identify Patient Factors Impacting Adherence to Oral Chemotherapy
Status: Enrolling
Updated:  11/18/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Patient Factors Impacting Adherence to Oral Chemotherapy
A Pilot Study to Identify Patient Factors Impacting Adherence to Oral Chemotherapy
Status: Enrolling
Updated: 11/18/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)
A Phase II Study of the Efficacy and Safety of AP23573 in Patients With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)
Status: Enrolling
Updated:  11/18/2015
Louis Warchaw Prostate Cancer Center, Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)
A Phase II Study of the Efficacy and Safety of AP23573 in Patients With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)
Status: Enrolling
Updated: 11/18/2015
Louis Warchaw Prostate Cancer Center, Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)
A Phase II Study of the Efficacy and Safety of AP23573 in Patients With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)
Status: Enrolling
Updated:  11/18/2015
Beth Israel Deaconess Medical Center/MGH/DFCI
mi
from
Boston, MA
Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)
A Phase II Study of the Efficacy and Safety of AP23573 in Patients With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)
Status: Enrolling
Updated: 11/18/2015
Beth Israel Deaconess Medical Center/MGH/DFCI
mi
from
Boston, MA
Click here to add this to my saved trials
Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)
A Phase II Study of the Efficacy and Safety of AP23573 in Patients With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)
Status: Enrolling
Updated:  11/18/2015
The Methodist Hospital Research Institute
mi
from
Houston, TX
Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)
A Phase II Study of the Efficacy and Safety of AP23573 in Patients With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)
Status: Enrolling
Updated: 11/18/2015
The Methodist Hospital Research Institute
mi
from
Houston, TX
Click here to add this to my saved trials
Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)
A Phase II Study of the Efficacy and Safety of AP23573 in Patients With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)
Status: Enrolling
Updated:  11/18/2015
University of Wisconsin, Madison, WI
mi
from
Madison, WI
Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)
A Phase II Study of the Efficacy and Safety of AP23573 in Patients With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)
Status: Enrolling
Updated: 11/18/2015
University of Wisconsin, Madison, WI
mi
from
Madison, WI
Click here to add this to my saved trials
A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies
A Multinational, Randomized, Double-blind Placebo Controlled Study of AVE8062 (25 mg/m2) Administered Every 3 Weeks in Patients With Advanced-stage Soft Tissue Sarcoma, Treated With Cisplatin (75 mg) After Failure of Anthracycline and Ifosfamide Chemotherapies.
Status: Enrolling
Updated:  11/18/2015
Clinical Research Facility
mi
from
Santa Monica, CA
A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies
A Multinational, Randomized, Double-blind Placebo Controlled Study of AVE8062 (25 mg/m2) Administered Every 3 Weeks in Patients With Advanced-stage Soft Tissue Sarcoma, Treated With Cisplatin (75 mg) After Failure of Anthracycline and Ifosfamide Chemotherapies.
Status: Enrolling
Updated: 11/18/2015
Clinical Research Facility
mi
from
Santa Monica, CA
Click here to add this to my saved trials
A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies
A Multinational, Randomized, Double-blind Placebo Controlled Study of AVE8062 (25 mg/m2) Administered Every 3 Weeks in Patients With Advanced-stage Soft Tissue Sarcoma, Treated With Cisplatin (75 mg) After Failure of Anthracycline and Ifosfamide Chemotherapies.
Status: Enrolling
Updated:  11/18/2015
Clinical Research Facility
mi
from
Orlando, FL
A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies
A Multinational, Randomized, Double-blind Placebo Controlled Study of AVE8062 (25 mg/m2) Administered Every 3 Weeks in Patients With Advanced-stage Soft Tissue Sarcoma, Treated With Cisplatin (75 mg) After Failure of Anthracycline and Ifosfamide Chemotherapies.
Status: Enrolling
Updated: 11/18/2015
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies
A Multinational, Randomized, Double-blind Placebo Controlled Study of AVE8062 (25 mg/m2) Administered Every 3 Weeks in Patients With Advanced-stage Soft Tissue Sarcoma, Treated With Cisplatin (75 mg) After Failure of Anthracycline and Ifosfamide Chemotherapies.
Status: Enrolling
Updated:  11/18/2015
Clinical Research Facility
mi
from
Maywood, IL
A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies
A Multinational, Randomized, Double-blind Placebo Controlled Study of AVE8062 (25 mg/m2) Administered Every 3 Weeks in Patients With Advanced-stage Soft Tissue Sarcoma, Treated With Cisplatin (75 mg) After Failure of Anthracycline and Ifosfamide Chemotherapies.
Status: Enrolling
Updated: 11/18/2015
Clinical Research Facility
mi
from
Maywood, IL
Click here to add this to my saved trials
A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies
A Multinational, Randomized, Double-blind Placebo Controlled Study of AVE8062 (25 mg/m2) Administered Every 3 Weeks in Patients With Advanced-stage Soft Tissue Sarcoma, Treated With Cisplatin (75 mg) After Failure of Anthracycline and Ifosfamide Chemotherapies.
Status: Enrolling
Updated:  11/18/2015
Clinical Research Facility
mi
from
Newark, NJ
A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies
A Multinational, Randomized, Double-blind Placebo Controlled Study of AVE8062 (25 mg/m2) Administered Every 3 Weeks in Patients With Advanced-stage Soft Tissue Sarcoma, Treated With Cisplatin (75 mg) After Failure of Anthracycline and Ifosfamide Chemotherapies.
Status: Enrolling
Updated: 11/18/2015
Clinical Research Facility
mi
from
Newark, NJ
Click here to add this to my saved trials
A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies
A Multinational, Randomized, Double-blind Placebo Controlled Study of AVE8062 (25 mg/m2) Administered Every 3 Weeks in Patients With Advanced-stage Soft Tissue Sarcoma, Treated With Cisplatin (75 mg) After Failure of Anthracycline and Ifosfamide Chemotherapies.
Status: Enrolling
Updated:  11/18/2015
Clinical Research Facility
mi
from
Philadelphia, PA
A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies
A Multinational, Randomized, Double-blind Placebo Controlled Study of AVE8062 (25 mg/m2) Administered Every 3 Weeks in Patients With Advanced-stage Soft Tissue Sarcoma, Treated With Cisplatin (75 mg) After Failure of Anthracycline and Ifosfamide Chemotherapies.
Status: Enrolling
Updated: 11/18/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies
A Multinational, Randomized, Double-blind Placebo Controlled Study of AVE8062 (25 mg/m2) Administered Every 3 Weeks in Patients With Advanced-stage Soft Tissue Sarcoma, Treated With Cisplatin (75 mg) After Failure of Anthracycline and Ifosfamide Chemotherapies.
Status: Enrolling
Updated:  11/18/2015
Clinical Research Facility
mi
from
San Antonio, TX
A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies
A Multinational, Randomized, Double-blind Placebo Controlled Study of AVE8062 (25 mg/m2) Administered Every 3 Weeks in Patients With Advanced-stage Soft Tissue Sarcoma, Treated With Cisplatin (75 mg) After Failure of Anthracycline and Ifosfamide Chemotherapies.
Status: Enrolling
Updated: 11/18/2015
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies
A Multinational, Randomized, Double-blind Placebo Controlled Study of AVE8062 (25 mg/m2) Administered Every 3 Weeks in Patients With Advanced-stage Soft Tissue Sarcoma, Treated With Cisplatin (75 mg) After Failure of Anthracycline and Ifosfamide Chemotherapies.
Status: Enrolling
Updated:  11/18/2015
mi
from
Bruxelles,
A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies
A Multinational, Randomized, Double-blind Placebo Controlled Study of AVE8062 (25 mg/m2) Administered Every 3 Weeks in Patients With Advanced-stage Soft Tissue Sarcoma, Treated With Cisplatin (75 mg) After Failure of Anthracycline and Ifosfamide Chemotherapies.
Status: Enrolling
Updated: 11/18/2015
mi
from
Bruxelles,
Click here to add this to my saved trials
Comparison of PEM Uptake Value (PUV) and Standardized Uptake Value (SUV) in Patients With Malignancies of the Breast
Pilot Study to Compare the PEM Uptake Value (PUV) and Standardized Uptake Value (SUV) in Patients With Malignancies of the Breast
Status: Enrolling
Updated:  11/19/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Comparison of PEM Uptake Value (PUV) and Standardized Uptake Value (SUV) in Patients With Malignancies of the Breast
Pilot Study to Compare the PEM Uptake Value (PUV) and Standardized Uptake Value (SUV) in Patients With Malignancies of the Breast
Status: Enrolling
Updated: 11/19/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Broccoli Sprout Extract in Treating Patients With Transitional Cell Bladder Cancer Undergoing Surgery
Pilot Pre-cystectomy Trial of Broccoli Extract in Patients With Superficial or Locally Advanced Bladder Cancer
Status: Enrolling
Updated:  11/19/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Broccoli Sprout Extract in Treating Patients With Transitional Cell Bladder Cancer Undergoing Surgery
Pilot Pre-cystectomy Trial of Broccoli Extract in Patients With Superficial or Locally Advanced Bladder Cancer
Status: Enrolling
Updated: 11/19/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Histologic Assessment of the Difference Between 18F-2-fluoro-2-deoxy_D-glucose Positron Emission Mammography(PEM) and Magnetic Resonance Imaging (MRI) of the Breast
Histologic Assessment of the Difference Between 18F-2-fluoro-2-deoxy_D-glucose Positron Emission Mammography(PEM) and Magnetic Resonance Imaging (MRI) of the Breast
Status: Enrolling
Updated:  11/19/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Histologic Assessment of the Difference Between 18F-2-fluoro-2-deoxy_D-glucose Positron Emission Mammography(PEM) and Magnetic Resonance Imaging (MRI) of the Breast
Histologic Assessment of the Difference Between 18F-2-fluoro-2-deoxy_D-glucose Positron Emission Mammography(PEM) and Magnetic Resonance Imaging (MRI) of the Breast
Status: Enrolling
Updated: 11/19/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Calcitriol and Dexamethasone Before Radical Prostatectomy in Treating Patients With Localized Adenocarcinoma (Cancer) of the Prostate
A Pilot Trial of Calcitriol in Localized Prostate Cancer: Investigation of Biologic Effects and Potential Intermediate Endpoints
Status: Enrolling
Updated:  11/19/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Calcitriol and Dexamethasone Before Radical Prostatectomy in Treating Patients With Localized Adenocarcinoma (Cancer) of the Prostate
A Pilot Trial of Calcitriol in Localized Prostate Cancer: Investigation of Biologic Effects and Potential Intermediate Endpoints
Status: Enrolling
Updated: 11/19/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer
Multicenter, Open Label, Phase II Clinical Study of Gemcitabine, Capecitabine and Avastin in Pancreatic Cancer
Status: Enrolling
Updated:  11/19/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer
Multicenter, Open Label, Phase II Clinical Study of Gemcitabine, Capecitabine and Avastin in Pancreatic Cancer
Status: Enrolling
Updated: 11/19/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer
Multicenter, Open Label, Phase II Clinical Study of Gemcitabine, Capecitabine and Avastin in Pancreatic Cancer
Status: Enrolling
Updated:  11/19/2015
Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer
Multicenter, Open Label, Phase II Clinical Study of Gemcitabine, Capecitabine and Avastin in Pancreatic Cancer
Status: Enrolling
Updated: 11/19/2015
Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer
A Multicenter Phase III Placebo-Controlled Trial of Celecoxib for Prevention of Capecitabine-Induced Palmar/Plantar (Hand/Foot) Syndrome in Patients With Metastatic Breast and Colorectal Cancer
Status: Enrolling
Updated:  11/19/2015
CCOP - Santa Rosa Memorial Hospital
mi
from
Santa Rosa, CA
Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer
A Multicenter Phase III Placebo-Controlled Trial of Celecoxib for Prevention of Capecitabine-Induced Palmar/Plantar (Hand/Foot) Syndrome in Patients With Metastatic Breast and Colorectal Cancer
Status: Enrolling
Updated: 11/19/2015
CCOP - Santa Rosa Memorial Hospital
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer
A Multicenter Phase III Placebo-Controlled Trial of Celecoxib for Prevention of Capecitabine-Induced Palmar/Plantar (Hand/Foot) Syndrome in Patients With Metastatic Breast and Colorectal Cancer
Status: Enrolling
Updated:  11/19/2015
CCOP - Grand Rapids
mi
from
Grand Rapids, MI
Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer
A Multicenter Phase III Placebo-Controlled Trial of Celecoxib for Prevention of Capecitabine-Induced Palmar/Plantar (Hand/Foot) Syndrome in Patients With Metastatic Breast and Colorectal Cancer
Status: Enrolling
Updated: 11/19/2015
CCOP - Grand Rapids
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer
A Multicenter Phase III Placebo-Controlled Trial of Celecoxib for Prevention of Capecitabine-Induced Palmar/Plantar (Hand/Foot) Syndrome in Patients With Metastatic Breast and Colorectal Cancer
Status: Enrolling
Updated:  11/19/2015
CCOP - Kalamazoo
mi
from
Kalamazoo, MI
Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer
A Multicenter Phase III Placebo-Controlled Trial of Celecoxib for Prevention of Capecitabine-Induced Palmar/Plantar (Hand/Foot) Syndrome in Patients With Metastatic Breast and Colorectal Cancer
Status: Enrolling
Updated: 11/19/2015
CCOP - Kalamazoo
mi
from
Kalamazoo, MI
Click here to add this to my saved trials